An End to Prostate Problems?

Breakthrough Detoxification Research Now Being Conducted
California, August 30, 2006. Prostate conditions such as prostatitis, enlarged prostate and prostate cancer are affecting men worldwide. In fact, more than 50% of all men 50 and over suffer from an enlarged prostate (Benign Prostate Hyperplasia or BPH). The problem gets worse as men age. That’s just one possible prostate condition. Another widespread affliction is prostatitis. It affects younger as well as older men.

This week, World Health Products received full Investigational Review Board (IRB) approval to conduct clinical trial on an innovative detoxifying product, Detoxamin®, in conjunction with the antibiotic, tetracycline. Pre-study trials indicate that this combination therapy will reduce or eliminate prostate problems. The study is slated to begin September 9, 2006 at the Tustin Longevity Center in Tustin, California under the direction of Rita Ellithorpe, MD, a specialist in integrative medicine.

A recent discovery has revealed a minute life form, much smaller than the smallest bacteria. It’s called nanobacteria. Many medical scientists believe these culprits cause hardening of the arteries, kidney stones and other degenerative conditions. These ultra microbes are thought to encase themselves in a shell of calcium. Researchers involved in this current study have uncovered convincing evidence pointing to nanobacteria forming calcifications or stones on the prostate. These continually growing stones are thought to cause pressure on the prostate giving rise to prostatitis and BPH. Studies suggest that calcium biofilm surrounding the nanobacteria can removed by an amino acid, EDTA, contained in a product called Detoxamin.

The nanobacteria are exposed and then destroyed by tetracycline. This one-two approach of killing the nanobacteria with tetracycline and dissolving the calcium deposits with Detoxamin is the foundation for conducting this study. There is evidence that EDTA also has beneficial results in diminishing hardening of the arteries, atherosclosis. Detoxamin also chelates or binds poisonous heavy metals within deep tissues and enables the body to easily eliminate the toxins through urine and feces. “Our clinical trial will determine if prostate calcifications will either reduce in size or be eliminated altogether. Furthermore, we will also find out if symptoms decrease or disappear,” says Larry Clapp, PhD, co-investigator and author of Prostate Health in 90 Days.

Toxic heavy metals have been implicated in many diseases of aging from Alzheimer’s, to cardiovascular disease. “I have over 500 patients with a variety of conditions in my practice that I placed on Detoxamin; the reason, because mostly everyone I have tested has a variety of heavy metal build up in their bodies. Detoxamin is a safe, effective and convenient way to remove these menacing toxins. Therefore, we eliminate the causative agents so that other therapies can work in combination and repair the damage heavy metals cause to cells, tissues and organs,” as stated by Dr. Ellithorpe, the Principle Investigator of the study. This new clinical study supports the use of combination therapy to curtail or eliminate the growing prostate problems.